Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, from Oct. 20-24. Presentations will feature new or updated findings from Merck’s broad portfolio of cancer medicines: KEYTRUDA, Merck’s anti-PD-1 therapy; WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor; LENVIMA® (lenvatinib), in collaboration with Eisai; and LYNPARZA® (olaparib), in collaboration with AstraZeneca, and emphasize Merck’s commitment to improving outcomes for patients across multiple stages of cancer.
Additionally, new data from Merck’s diverse pipeline will be shared at the congress, including from MK-1084, a KRAS G12C inhibitor being evaluated as monotherapy and in combination with KEYTRUDA; from MK-2870 (also known as SKB264), an anti-TROP2 antibody drug conjugate (ADC) being developed in collaboration with Kelun-Biotech; and from V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT) being developed in collaboration with Moderna, in combination with KEYTRUDA.
“At ESMO 2023, we look forward to sharing new research highlighting the breadth of our portfolio and expanding pipeline, as we pursue breakthrough innovations in oncology to address critical gaps in care for patients in need,” said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. “Our continued efforts to treat cancer earlier and make a meaningful impact are fueled by one goal: To give those who are counting on us more effective ways to treat their cancer.